SCP Standard Capital Partners AG
1.97
EUR
-0.11
(-5.29%)
ISIN
DE000A12UPJ7
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Fabian Becker
- Full Time Employees
- 17
- Sector
- Consumer services
- Industry
- Movies/Entertainment
- Address
- Holzstrasse 30 Munich BY Germany 80469
- IPO Date
- Sep 23, 2015
- Website
- pantaflixgroup.com
- Similar Companies
- Business
- PAL Next AG (PAL.DE) is a technology company focused on developing and commercializing advanced diagnostic solutions for personalized medicine, particularly in oncology and precision healthcare. The company offers AI-powered diagnostic platforms, next-generation sequencing (NGS) services, and companion diagnostics; its core products include the PAL Next Diagnostic Platform for tumor profiling, targeted therapy matching services using liquid biopsies, and bioinformatics software for genomic data analysis under the PAL Next brand. PAL Next AG operates primarily in Europe, with expansion into North America, serving pharmaceutical companies, clinical labs, and healthcare providers in the precision oncology segment. Founded in 2020 and headquartered in Munich, Germany, the company emphasizes scalable, AI-driven tools for real-world evidence generation and therapy response prediction, targeting biotech firms and oncologists seeking data-driven treatment decisions. It maintains subsidiaries in bioinformatics and lab services, with no disclosed parent company. In the last year, PAL Next AG announced a strategic partnership with a leading European pharma giant for co-developing NGS-based companion diagnostics in Q1 2025; completed a EUR 25 million Series B funding round led by High-Tech Gründerfonds in June 2025 to fuel platform commercialization; and launched its upgraded PAL Next AI Analytics Suite in October 2025, enhancing predictive modeling for immunotherapy outcomes. These moves support geographic expansion into the U.S. market and a shift toward integrated digital health ecosystems.